LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
31 funds hold it · Insiders net selling
Net selling: insiders sold $66.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Financial period
Third Quarter 2026
Earnings per share
-$2.38 expected
Estimates as of Nov 10, 2026
EPS expected
-$2.03 to -$0.53
Revenue expected
19 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | -$1.90est. -$2.38 | +20.21%beat | $197.6MSEC filing | No year-ago quarter |
| Jun 30, 2026Reported Aug 5, 2026 | -$3.06est. -$2.06 | -48.77%miss | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2026Reported May 6, 2026 | -$2.29est. -$1.84 | -24.61%miss | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2025Reported Feb 25, 2026 | -$1.86est. -$1.56 | -18.87%miss | $0.00Alpha Vantage | -100.0%from $261.6M |
| Sep 30, 2025Reported Nov 5, 2025 | -$1.61est. -$1.39 | -15.83%miss | $0.00SEC filing | No year-ago quarter |
| Jun 30, 2025Reported Aug 6, 2025 | -$1.31est. -$1.12 | -16.96%miss | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2025Reported May 7, 2025 | -$1.13est. -$1.06 | -6.60%miss | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2024Reported Feb 26, 2025 | -$1.12est. -$0.96 | -16.12%miss | $261.6MAlpha Vantage | +35155.0%from $742.0K |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $197.6M |
| Cost of what it sold | $4.7M | $4.5M | — | $327.0K |
| Gross profit | -$4.7M | -$4.5M | — | $197.2M |
| What it spent | ||||
| Research and development | $292.6M | $344.0M | $394.9M | $417.1M |
| Sales and admin | $64.3M | $101.3M | $110.2M | $153.3M |
| Other operating costs | — | -$4.5M | — | — |
| Total operating expenses | $356.9M | $440.7M | $505.1M | $570.4M |
| What was left | ||||
| Operating profit | -$361.6M | -$445.2M | -$505.1M | -$373.1M |
| Interest on debt | $11.9M | $12.2M | $23.8M | $33.8M |
| Profit before tax | -$364.9M | -$453.8M | -$644.4M | -$409.8M |
| Tax | — | — | — | -$2.4M |
| Net profit | -$364.9M | -$453.8M | -$644.4M | -$407.5M |
| EBITDA | -$348.3M | -$437.1M | -$616.1M | -$373.0M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Revolution Medicines officer sells $162,200 in shares
NeutralNov 13After exercising options, Revolution Medicines (RVMD) officer sells 811 shares at $200 each.
NeutralNov 12What Sent Revolution Medicines Stock Lower?
Leans bearishNov 12Revolution Medicines (RVMD) Stock Dropped, So What Is Driving Attention Now?
Leans bullishNov 12Form 4 Revolution Medicines Inc For: 7 November By Investing.com
NeutralNov 7Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats Up
BullishNov 7Revolution Medicines Announces FDA Approval of RAS(ON) Inhibitor and Q3 2026 Progress
BullishNov 7What Just Happened To Revolution Medicines Stock?
NeutralNov 734 macro signals shaping RVMD right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
